AGP Executive Report
Last update: 18 hours agoCancer Research in NJ: Bristol Myers Squibb reported late-breaking Phase 3 results at ASCO showing its oral multiple myeloma drug mezigdomide (MeziKd) cut the risk of progression or death by 52% versus standard carfilzomib/dexamethasone, with median progression-free survival rising to 18 months. Prostate Cancer & Brain Health: In a New Jersey-linked Phase II head-to-head trial, Bayer’s NUBEQA (darolutamide) showed less decline in objective cognitive performance over 24 weeks than enzalutamide for men with advanced prostate cancer. AI Backlash Hits NJ: A new Gallup poll finds 71% of Americans oppose AI data center construction locally, echoing mounting community fights over power, water, and utility bills. World Cup Security Tech: The FBI is training regional teams for an anti-drone taskforce to protect fans amid fears of drone misuse at major events. Aviation Innovation: Electra completed the first urban demo of its hybrid-electric ultra-short aircraft, aiming to bring regional flights closer to where people live. Public Safety: A Spalding County arrest in Georgia charges a man with a 1989 Bayonne homicide, pending extradition to New Jersey.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.